The Sioux Community Cancer Consortium (SCCC) is a multidisciplinary group of physicians and allied medical professionals in the cities of Sioux Falls, South Dakota and Sioux City, Iowa dedicated to producing high quality clinical cancer treatment research and cancer control research in a community setting. This quality clinical cancer research is possible because of the dedicated physician staff, an excellent data management support team, and a quality treatment research RN and cancer control RN/data management support team. The SCCC is the only immediately available source of clinical cancer research sponsored by the National Cancer Institute in the Sioux Falls, South Dakota and Sioux City, Iowa communities and their regional referral areas. The geographic catchment area for the Sioux City Cancer Consortium covers 105,000 square miles in the eastern half of South Dakota, southwest Minnesota, northwest Iowa, and northeast Nebraska (depicted on page 47 as a map presentation). The SCCC has been a funded member of the NCI CCOP program since its establishment in 1983. During grant year 5 (1988-1989) the combined accrual of the Sioux Fails and Sioux City components was 126 cancer treatment cases and 66.05 NCI cancer control credits. Accrual during June and July 1989 (1st 2 months of grant year 6) was 26 cancer treatment cases (150 annualized cancer treatment cases per year), and cancer control NCI credits during this same period were 8.85 (annualized 53.1 credits/year). The research base for the SCCC will remain the North Central Cancer Treatment Group (NCCTG). Through the North Central Cancer Treatment Group and the Mayo Comprehensive Cancer Center, the SCCC will continue affiliations with the Eastern Cooperative Oncology Group (ECOG) and the Children's Cancer Study Group (CCSG). The continued specific objective of this application is to continue to make available to patients in this region the availability of quality NCI sponsored clinical cancer treatment research protocols and cancer control research protocols. One of the goals of the Sioux Community Cancer Consortium is to enter 150 patients per year on clinical cancer treatment protocols and to enter an appropriate number of patients on cancer control research protocols to achieve 50 cancer control credits per year. This is a realistic goal based on the past accomplishment of the participating members of the Sioux Community Cancer Consortium.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035103-10
Application #
3557497
Study Section
Special Emphasis Panel (SRC (54))
Project Start
1987-08-30
Project End
1994-05-31
Budget Start
1993-06-01
Budget End
1994-05-31
Support Year
10
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Central Plains Clinic, Ltd.
Department
Type
DUNS #
City
Sioux Falls
State
SD
Country
United States
Zip Code
57105
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Schneider, Bryan P; O'Neill, Anne; Shen, Fei et al. (2015) Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Br J Cancer 113:1651-7
Liu, Heshan; Tan, Angelina D; Qin, Rui et al. (2015) Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. SOJ Anesthesiol Pain Manag 2:
Wagner-Johnston, Nina D; Sloan, Jeff A; Liu, Heshan et al. (2015) 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer 121:2537-43

Showing the most recent 10 out of 72 publications